Skip to content
TirzepatideReport

Tirzepatide monograph · Evidence review

Measured Tirzepatide Review: Cost, a Misleading Microdose Headline & Honest Verdict (2026)

An honest 2026 review of Measured tirzepatide — a $79 microdose headline that's a promo rate on an unlabeled dose, plus real brand and insurance options.

Researched & written by Alan Pierce · last updated

Clinical Pharmacology Writer

FDA warning letter
FDA issued Better Health Labs, Inc. dba Measured a warning letter in February 2026 (False & Misleading Claims/Misbranded (Telehealth)). Read the letter on FDA’s own warning-letter database.

On this page

Editorial pick

CoreAge Rx

$149/mo flat

Doctor-reviewed tirzepatide with one flat price and built-in human support.

Advertising disclosure · we may earn a commission at no extra cost to you.

Check availability
vs median
$120/mo below the $269 median
Market
$109–$429/mo across 396 providers
Dispensed
Compounded tirzepatide (503A)

Popular alternative

Peter MD

Physician-prescribed tirzepatide with a low $149 entry — after which it's billed quarterly, not monthly, and a broad state exclusion list applies.

$149 first mo, then $249/mo (billed quarterly)

Check Peter MD availability

Measured's headline "$79 GLP-1 Microdose" price is worth reading closely: it's a promotional rate off a $99 list price, filed by the provider under longevity rather than weight loss, and is not a labeled therapeutic dose of either semaglutide or tirzepatide. Every fact here comes from the company's own published program.

A misleading microdose headline

This is the most important thing to understand about Measured's pricing is the $79 "GLP-1 Microdose" figure most prominently advertised is a promotional rate off a $99 list price, and Measured itself files it under longevity, not weight loss — it is not a labeled therapeutic dose of semaglutide or tirzepatide. The actual weight-loss-labeled compounded doses start higher: $119/month for semaglutide, $229/month for tirzepatide.

§ Measured — Headline Price vs. Actual Therapeutic Dose

ItemDetail
Headline "$79 microdose"Promo off $99 list; filed under longevity, not a labeled dose
Compounded semaglutideFrom $119/mo
Compounded tirzepatideFrom $229/mo
The $79 figure is a promotional, non-labeled longevity microdose — not the therapeutic weight-loss price.

What Measured is

Measured is a metabolic-health membership, pairing GLP-1 treatment with 1:1 nutrition support and board-certified provider care. It offers both compounded and brand-name Wegovy/Zepbound in one place, with insurance or cash-pay options for the branded medications and an oral Wegovy pill option.

What Measured costs

Branded plans run on a $49/month membership with medication billed separately at $149 to $449/month depending on the drug and dose. Compounded tirzepatide starts from $229/month. The site never states which billing term its "from" prices assume, though monthly, quarterly, semi-annual, and annual terms are all offered — confirm which one you're being quoted.

The brand-vs-compounded question

Measured offers both compounded and brand-name tirzepatide (Zepbound) — a real choice most compounded-only sellers don't give you. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials; the brand option is the exact molecule and dose that was. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Measured's real strengths: 1:1 nutrition support bundled into the membership, both compounded and brand-name options, insurance-eligible branded plans, an oral option, and a cancel-anytime membership. The trade-offs, and the most important one this review flags directly: the $79 headline price is a promotional microdose rate, not a therapeutic weight-loss dose, the real branded cost structure splits a $49 membership fee from medication billed separately at $149-$449/month, no state count is published, and the billing term behind "from" prices is unstated. As with any GLP-1 program, and especially one with a headline price this easy to misread, get the actual therapeutic-dose price confirmed in writing before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-11, and better than semaglutide head-to-head2 — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Measured's bundled nutrition support and dual brand-and-compounded pathway are real strengths, but its $79 headline price is a promotional, non-therapeutic microdose rate — the actual weight-loss compounded tirzepatide starts at $229/month, and branded plans split a separate $49 membership fee from medication cost. Read past the headline before comparing it to other providers. For a similarly bundled, dietitian-supported program with clearer flat pricing, compare it against CoreAge Rx or Freya Meds. See our best tirzepatide providers ranking for the full field.

Frequently asked questions

Is Measured's $79 price the real cost of tirzepatide?

No — the $79 figure is a promotional "GLP-1 Microdose" rate filed under longevity, not a labeled therapeutic weight-loss dose. Actual compounded tirzepatide starts from $229/month.

Does Measured offer brand-name tirzepatide?

Yes — Zepbound is available alongside compounded options, with insurance or cash-pay billing separate from a $49/month membership fee.

Does Measured include nutrition support?

Yes — the membership bundles 1:1 nutrition support with board-certified provider care.

References(2)

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
  2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Bays HE, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/

About the author

Alan Pierce

Clinical Pharmacology Writer

About Tirzepatide Report · How we verify prices · This page last updated August 2026

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Related monograph sections

View all sections